- Home
- MTLS vs PRTA Comparison
MTLS vs PRTA Comparison
Compare MTLS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- PRTA
- Stock Information
- Founded
- MTLS 1990
- PRTA 2012
- Country
- MTLS Belgium
- PRTA Ireland
- Employees
- MTLS N/A
- PRTA N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- PRTA Health Care
- Exchange
- MTLS Nasdaq
- PRTA Nasdaq
- Market Cap
- MTLS 349.7M
- PRTA 472.1M
- IPO Year
- MTLS 2014
- PRTA N/A
- Fundamental
- Price
- MTLS $5.13
- PRTA $8.20
- Analyst Decision
- MTLS
- PRTA Buy
- Analyst Count
- MTLS 0
- PRTA 10
- Target Price
- MTLS N/A
- PRTA $14.86
- AVG Volume (30 Days)
- MTLS 127.2K
- PRTA 1.2M
- Earning Date
- MTLS 10-23-2025
- PRTA 08-04-2025
- Dividend Yield
- MTLS N/A
- PRTA N/A
- EPS Growth
- MTLS N/A
- PRTA N/A
- EPS
- MTLS 0.11
- PRTA N/A
- Revenue
- MTLS $311,850,851.00
- PRTA $10,341,000.00
- Revenue This Year
- MTLS $2.98
- PRTA N/A
- Revenue Next Year
- MTLS $7.09
- PRTA $389.77
- P/E Ratio
- MTLS $48.31
- PRTA N/A
- Revenue Growth
- MTLS 2.98
- PRTA N/A
- 52 Week Low
- MTLS $3.93
- PRTA $4.32
- 52 Week High
- MTLS $9.69
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- MTLS 47.90
- PRTA 58.73
- Support Level
- MTLS $5.01
- PRTA $8.05
- Resistance Level
- MTLS $5.32
- PRTA $8.73
- Average True Range (ATR)
- MTLS 0.18
- PRTA 0.38
- MACD
- MTLS 0.02
- PRTA -0.05
- Stochastic Oscillator
- MTLS 52.08
- PRTA 47.62
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.